Q4FY22 Result Update - Syngene International - ICICI Direct

Syngene reported upbeat numbers led by Development Services.

- Revenues grew 15% YoY to Rs. 758 crore

- EBITDA margins improved 31 bps YoY to 33%

- Net profit was at Rs. 148 crore (up 7% YoY)

Key triggers for future price performance

- The client base has grown from 256 to 420 over FY16-22, and multiple year extension of Amgen, BMS, Baxter contracts makes it well poised to capitalise on growing opportunities globally

- SynVent, Syngene's Integrated Drug Discovery (IDD) platform ability to expand business from existing clients and attract new clients

- Expansion of Biopharma manufacturing business by commissioning cGMP microbial facility and expanding the mammalian cell manufacturing facility

- Regulatory approvals from regulated markets for Mangalore facility

For details, click on the link below: Link to the report

Shares of Syngene International Limited was last trading in BSE at Rs. 626.30 as compared to the previous close of Rs. 623.70. The total number of shares traded during the day was 13102 in over 939 trades.

The stock hit an intraday high of Rs. 637.15 and intraday low of 620.20. The net turnover during the day was Rs. 8249752.00.

Source : Equity Bulls

Keywords

SyngeneInternational INE398R01022 Q4FY22 ResultUpdate ICICIDirect